Edwards Lifesciences stock falls 1.26 percent on legal news

Edwards Lifesciences stock fell 1.26 percent to USD 85.73 on the NYSE on September 24, 2026, as a USD 39 million securities class action settlement put a legal issue alongside the company's latest operating figures. ClaimDepot reported the settlement on September 24, 2026.

Settlement meets double digit growth

The settlement covers investors who purchased Edwards Lifesciences common stock between February 6, 2024, and July 24, 2024. The claim deadline is December 2, 2026, while a fairness hearing is scheduled for December 16, 2026, according to ClaimDepot.

The legal payment compares with a growing operating base. In the quarter ended June 30, 2026, sales increased 13.6 percent year over year to USD 1.74 billion, while TAVR sales rose 11.3 percent to USD 1.26 billion, according to Business Wire.

EPS beat remains the key comparison

Adjusted EPS was USD 0.78 in Q2 2026, above the USD 0.74 consensus estimate. The comparison matters because the quarter also produced USD 241.4 million in consolidated net income and a 29 percent operating margin in the standardized financial data.

Management's published Q2 figures show that revenue expansion continued even as consolidated net income was below the USD 333.2 million reported for Q2 2025. That split makes sales growth and earnings quality the more important operating measures for the next report.

Analyst target stays above market

On September 11, 2026, BTIG Research reaffirmed its Buy rating and USD 110 price target, according to MarketBeat. That target stands USD 24.27 above the September 24 price, while the stock's 52-week range is USD 72.30 to USD 96.29.

Stock remains below yearly high

Edwards Lifesciences stock stood at USD 85.73 on the NYSE on September 24, 2026, down USD 1.09 from the prior close. Its market capitalization was USD 49,363,334,000 on the same date, giving the settlement and the Q2 growth figures a clear valuation context.